This report evaluates the analytical validity, clinical validity, and clinical utility of the DCISionRT (Prelude Corp.) test.
Precision MedicineThe explosion of genetic and molecular medicine has produced mountains of options and evidence. Conversely, there is often an alarming lack of evidence. This is where we come in.
We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:
- Will testing change patient management for this indication?
- If so, what tests and/or therapies should I use?
- Should we cover testing and/or therapies?
- Can we manage these services internally?
This report evaluates the analytical validity, clinical validity, and clinical utility of the clonoSEQ test (Adaptive Biotechnologies) specific to U.S. Food and Drug Administration (FDA)-cleared intended use.
This report reviews the use of genetic testing for fibrous dysplasia/McCune-Albright syndrome.
This report evaluates the clinical utility of the MI Profile test for the intended use as a broad molecular profiling tool.
FoundationOne CDx (Foundation Medicine Inc.) for the Intended Use as a Broad Molecular Profiling Tool
This report evaluates the clinical utility of the FoundationOne CDx test for the intended use as a broad molecular profiling tool.
This report evaluates the analytical validity, clinical validity, and clinical utility of the PrismRA test. According to the laboratory, the PrismRA molecular signature test identifies which patients with rheumatoid arthritis (RA) are unlikely to respond to tumor necrosis factor-ɑ inhibitor (TNFi) therapies to help guide …
This report reviews the use of preimplantation genetic testing for polygenic disorders (PGT-P) using polygenic risk scores for the purpose of embryo selection.
This report evaluates the analytical validity, clinical validity, and clinical utility of the DecisionDx-Melanoma test.
This report evaluates the use of whole exome sequencing (WES) or whole genome sequencing (WGS) to inform clinical action and improve patient outcomes in adults > 18 years of age with undefined neurological phenotypes suggestive of neuromuscular disease or movement disorders who have had no definitive diagnosis following standard diagnostic tests.
This report evaluates the clinical utility of cell-free DNA (cfDNA) (formerly NIPS, NIPT) screening for fetal chromosomal copy number variants (CNVs) in women with singleton or twin pregnancies.